Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods
This represented a 515% restriction relative to the standard average intake of control mice and was based on the measured food intake of 9-day ICV leptin-treated C3H/HeJ mice
you need the milligram count that actually reaches your mitochondria
Pandoras Box: Uncertain Ingredients and Uncontrolled Quality Unlike their FDA-approved counterparts, compounded GLP-1s lack standardized ingredients and rigorous quality control measures
Below is a realistic guide used at a doctor-led clinic in Hauz Khas, South Delhi
J Clin Endocrinol Metab (2018) 103(5):180412
